Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

4 treatments under study, led by Tranexamic Acid

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 42/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results67% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
Phase 3 (1)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04941729Not ApplicableTerminated

Study to Evaluate the Safety and Efficacy of OR3O™ Dual Mobility System vs. Conventional Single Bearing Design Total Hip System

NCT00939900Phase 3CompletedPrimary

Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head

NCT02146456Not ApplicableCompletedPrimary

Rotational Thromboelastography Study in Tranexamic Acid and Colloid Infusion

Showing all 3 trials

Research Network

Common Treatments

  • Tranexamic Acid1
  • Or3o Dual Mobility System1
  • Zoledronic Acid Aclasta1
  • Conventional1

Active Sponsors

  • Seoul National University Bundang Hospital2
  • Novartis Korea Ltd.1
  • Smith & Nephew Medical (Shanghai) Ltd1

Top Investigators

Related Conditions

  • Rheumatoid Arthritis Ra1
  • Femoral Neck Fractures1
  • Hip Dislocation1
  • Degenerative Hip Joint Disease1
  • Osteoarthritis Oa1

Activity Timeline